Johnson & Johnson's Q2 2024 earnings call showed strong Innovative Medicine performance, driven by key brands and new product uptake.  Management expressed confidence in the company's ability to offset MedTech's below-expectation growth in the second quarter and anticipate market growth accelerating in the second half of the year, particularly in cardiovascular and orthopedics.  The talk of various regulatory approvals and clinical trials suggests potential catalysts for future growth.

[1]
